656 A phase 1/2 trial in progress of MK-6070 (aka HPN328), a DLL3-targeting T cell engager, as monotherapy or combination therapy for advanced cancers associated with DLL3 expression
Prantesh Jain(Roswell Park Comprehensive Cancer Center), Himisha Beltran(Dana-Farber Cancer Institute), Hirva Mamdani(Wayne State University), Jonathan R. Thompson, Afshin Dowlati(University Hospitals of Cleveland), K. Nathan Sankar(Cedars-Sinai Medical Center), Alissa J. Cooper(Massachusetts General Hospital), Melissa L. Johnson(Tennessee Oncology), Erin L. Schenk(University of Colorado Anschutz Medical Campus), Rachel E. Sanborn(Providence Portland Medical Center), Rahul Aggarwal(UCSF Helen Diller Family Comprehensive Cancer Center), Ann W. Gramza(Rapt Therapeutics (United States))
Cited by 2
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
|Cancer Discovery|2017|964
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835